Gilead Sciences Inc.
Organization's Own Description:
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases around the world.
Our portfolio of 13 marketed products includes a number of category firsts and market leaders, including Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) – the first single-tablet regimen for HIV infection. Viread® (tenofovir disoproxil fumarate), the company’s first agent approved for HIV infection, was also approved in 2008 for the treatment of chronic hepatitis B. Chronic hepatitis B, a serious liver disease caused by the hepatitis B virus (HBV), is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States. read more